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RDP58 is the ﬁrst lead compound in a series of immunomodulating decapeptides discovered through activity-based
screening and computer-aided, rational design. RDP58 disrupts cellular responses signaled through the Toll-like and
tumor necrosis factor (TNF) receptor families and occludes important signal transduction pathways involved in
inﬂammation, inhibiting the production of tumor necrosis factor alpha (TNFa), interferon-c, interleukin (IL)-2, IL-6, and
IL-12. These pro-inﬂammatory cytokines are thought to be involved in the pathogenesis of several inﬂammatory and
autoimmune diseases, including atopic dermatitis and psoriasis. The goal of this study was to determine the ability of
RDP58 to inhibit skin inﬂammation following exposure to the well-characterized protein kinase C activator and tumor
promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Topical application of RDP58 to the epidermis following TPA
treatment resulted in the amelioration of the phorbol ester-induced irritant contact dermatitis. Substantial reductions
were observed in skin thickness and tissue weight, neutrophil-mediated myeloperoxidase activity, inﬂammatory
cytokine production, and various histopathological indicators. We also found RDP58 to be effective in reducing the
compounding inﬂammatory damage brought on by chronic TPA exposure, and that it is capable of targeting inﬂam-
matory mediators specifically in the keratinocyte. These results demonstrate that topically applied RDP58 is an
effective anti-inﬂammatory treatment in the phorbol ester-induced dermatitis model, and suggest that it may have
therapeutic potential in a variety of immune-related cutaneous diseases.
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The skin plays a central role in host immunological de-
fenses; however, the regulation of these defense mecha-
nisms is also crucial, as inappropriate or misdirected
immune activity is implicated in the pathogenesis of a large
variety of acquired inflammatory skin disorders (Kupper and
Fuhlbrigge, 2004). High levels of inflammatory cytokines
and reactive oxygen species are proposed contributors to
the pathophysiologic mechanisms associated with various
inflammatory dermatoses (Elias et al, 1999; Trouba et al,
2002). It is widely recognized that the secretions of
cytokines by keratinocytes in response to injury, particular-
ly tumor necrosis factor alpha (TNFa) and interleukin (IL)1a,
are key mediators of the cutaneous inflammatory response.
Both the epithelial barrier cells and resident innate immune
cells in the skin express receptors belonging to the Toll-like
receptor (TLR) family (Takeda et al, 2003). The binding of
TLR ligands, which include a number of pathogen-associ-
ated molecular pattern molecules, is associated with the
recruitment of intracellular adaptor proteins similar to those
used by IL-1R and subsequent activation of the JUN N-
terminal kinase (JNK) and nuclear factor-kB (NF-kB) signa-
ling pathways. The NF-kB signaling pathway is seen as a
key link between the innate and adaptive immune systems
(Medzhitov and Janeway, 1997). In the skin, NF-kB regu-
lates the expression of numerous genes that are involved in
the initiation of the inflammatory response, including adhe-
sion molecules, chemokines and cytokines, matrix metallo-
proteases, nitric oxide synthase, and enzymes that control
prostaglandin synthesis (Bell et al, 2003). Beyond the direct
effects of these compounds on pathogens and abnormal
cells, products of the innate immune response direct the
recruitment of additional leukocytes to the site of activation.
These include non-specific leukocytes, such as neutrophils
and natural killer cells, as well as key components of the
adaptive immune system, such as effector T cells.
We have developed an immunomodulatory peptide,
RDP58, which is both an effective inhibitor of multiple pro-
inflammatory cytokines (Iyer et al, 2002) and an upregulator
of an oxidative stress-responsive enzyme, heme oxygen-
ase-1 (HO-1) (Iyer et al, 1998; Cuturi et al, 1999). RDP58,
NH2–r–nle–nle–nle–r–nle–nle–nle–g–y–CONH2, is the lead
compound in a series of protease-resistant, D-isomeric
decapeptides discovered through activity-based screening
Abbreviations: IL, interleukin; MPO, myeloperoxidase; NHEK, nor-
mal human epidermal keratinocytes; RDP58, rationally designed
peptide 58; TNFa, tumor necrosis factor alpha; TPA, 12-O-tetrad-
ecanoylphorbol-13-acetate
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and computer-aided, rational design (Grassy et al, 1998;
Iyer et al, 2002). Originally derived from sequences of hu-
man class I MHC molecule known to have clinically impor-
tant immunomodulating effects (Cuturi et al, 1995; Gao et al,
1996; Hanaway et al, 1996), it has recently been discovered
that RDP58 is the first of a novel class of anti-inflammatory
therapeutics that disrupt formation of the TRAF6–MyD88–
IRAK complex responsible for activating crucial signal
transduction pathways (p38MAPK, JNK, and IKK) involved
in inflammation (Lazarov et al, 2003).1 Because multiple,
parallel pathways are affected, RDP58 inhibits the produc-
tion of several pro-inflammatory cytokines, including TNFa,
interferon-g, IL-2, IL-6, and IL-12, in both immune and ep-
ithelial cell types. These pro-inflammatory cytokines are
thought to be involved in the pathogenesis of numerous
inflammatory and autoimmune diseases. To date, the
RDP58 peptide has demonstrated efficacy in a variety of
inflammatory disease models, including UVB-induced skin
injury, collagen-induced arthritis, graft-versus-host disease,
allograft rejection, and inflammatory bowel disease (Buelow
et al, 1995; Gao et al, 1996; Oberyszyn et al, 2001; Bois-
menu et al, 2002; Iyer et al, 2002; Murthy et al, 2002). The
ability of RDP58 to utilize the HO-1 pathway, a stress re-
sponse mechanism for protecting cells from oxidative injury,
was demonstrated by the administration of peptide to mice
and rats, which resulted in an increase in HO-1 expression
that correlated with cardiac allograft survival (Iyer et al,
1998; Cuturi et al, 1999). These studies suggest that RDP58
may be an effective therapy for inflammation by combining
anti-inflammatory properties with the ability to induce stress
response pathways that mitigate oxidative damage.
In this study, we determined whether topical treatment
with RDP58 would reduce cutaneous inflammation in the
skin of mice following exposure to the well-characterized
protein kinase C activator and tumor promoter 12-O-tet-
radecanoylphorbol-13-acetate (TPA). We also investigated
the effects of RDP58 on keratinocytes, as they represent the
likely targeted cell type. Our studies demonstrate that top-
ically applied RDP58 possesses potent anti-inflammatory
activity in both acute and chronic contact dermatitis models
and that keratinocytes are in fact highly responsive to this
immunomodulatory peptide.
Results
RDP58 inhibits TPA-induced cutaneous inﬂammation
We first assessed the anti-inflammatory activity of RDP58 in
the TPA model of acute irritant contact dermatitis. Increased
skin thickening is often the first hallmark of skin irritation and
local inflammation. This parameter is indicative of a number
of processes that occur during skin inflammation, including
increased vascular permeability, edema and swelling within
the dermis, and proliferation of the epidermal keratinocytes.
Skin thickness was measured in the dorsal skin prior to and
18 h following treatments using digital calipers, and results
Figure1
Rationally designed peptide 58 (RDP58) reduces 12-O-tetrad-
ecanoylphorbol-13-acetate (TPA)-induced skin and ear swelling.
Skin thickness (A, C) and weight (B) are markedly increased in
TPA-induced irritant dermatitis. Topical treatment with RDP58 (10
and 2 mg per mL), or a positive control corticosteroid, 0.05% beta-
methasone, 30 min following TPA application reduces the increases
in dorsal skin thickness (A) and weight (B) as well as ear thickening (C),
whereas water-vehicle alone has no effect. Thickness measure-
ments were made using digital calipers and expressed as the differ-
ence between 0 and 18 h measurements in dorsal skin thickness or as
the percent change in thickness relative to naı¨ve, untreated ear tissue.
Skin biopsies were collected from the dorsal skin for weight measure-
ments. Data are presented as mean  SEM from to to three experi-
ments consisting of three to five animals per group in each experiment.
Statistical significance was determined using Student’s unpaired t test;
po0.05.
1Lazarov M, Welihinda A, Muhr E, Mo L, Buelow R, Fong T:
RDP58, a novel anti-inflammatory Peptide, Inhibits Multiple Intra-
cellular Messenger Pathways and transcription factors to block
TNFa, IFNg, and IL12 production. In Research Forum—America,
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were graphed as the difference in skin thickness expressed
in mm2. Exposure of the dorsal epidermis of FVB/N mice
to TPA resulted in marked increases in both skin thickness
(Fig 1A) and tissue weight (Fig 1B). Topical application of
acetone or RDP58 alone did not alter the skin thickness
significantly. Treatment with RDP58 30 min after TPA appli-
cation, however, significantly inhibited the phorbol ester-
induced increase in both skin thickness (65% decrease;
po0.0001) and weight (30% decrease; po0.01), indicating
a therapeutic effect of this peptide (Fig 1A, B).
The ability of RDP58 to reduce cutaneous inflammation
as related to a change in skin thickening was also observed
in the ear (Fig 1C). The experimental design used with ear
applications allowed for normalization between treated and
untreated ears from the same animal from which a mean
change in thickness relative to naı¨ve tissue was established
in each treatment group (n¼5). Treatment with RDP58 re-
sulted in an approximately 60% decrease in TPA induced
ear thickening (po0.0001), which was comparable with the
potent topical corticosteroid betamethasone. The ability of
RDP58 to reduce ear thickness was diminished at a lower 2
mg per mL concentration (Fig 1C), indicating a specific
concentration dependence of this effect.
We next examined hematoxylin and eosin (H&E)-stained
sections of the ears from TPA-treated animals. As shown in
Fig 2, TPA application results in a marked increase in ear
thickness, with clear evidence of edema, epidermal hype-
rplasia, and large numbers of inflammatory cells infiltrating
the dermis (A vs B). RDP58 treatment reduced ear thickness
and the associated pathological indicators to an extent
comparable with betamethasone (Fig 2C, D). These results
provide further evidence that RDP58 ameliorates TPA-in-
duced contact dermatitis, directly illustrating its effects
within the target tissue.
RDP58 reduces neutrophil activation and pro-inﬂamma-
tory cytokine production in vivo To assess the efficacy of
RDP58 at the cell and molecular level, we next looked at
Figure 2
Rationally designed peptide 58 (RDP58) reduces histopathology associated with skin inflammation. Hematoxylin- and eosin-stained sections
of normal mouse ear (A), 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced irritant dermatitis (B), 0.05% betamethasone (C), and 10 mg per mL
RDP58 treated (D). TPA treatment induced a marked increase in ear thickness accompanied by the characteristic pathological features of edema,
epidermal hyperplasia, and inflammatory cell infiltration (B). RDP58 treatment reduces ear thickness and the associated pathological indicators to an
extent comparable with betamethasone (C vs D). Sections shown are representative of observations from five animals in each group.
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prominent inflammatory mediators in the skin. The TPA-in-
duced acute inflammatory response in skin is associated
with an increase in the infiltration of activated neutrophils
into the dermis. These activated neutrophils produce my-
eloperoxidase (MPO), which can be quantitated as a meas-
ure of the magnitude of neutrophil activation (Bradley et al,
1982). Topical application of TPA to the dorsal skin of FVB/N
mice substantially increased the amount of MPO detected
within the skin at 18 h (Fig 3A). Compared with vehicle
alone, treatment with 10 mg per mL RDP58 30 min after TPA
exposure significantly decreased the dermal MPO activity
detected at 18 h (50% decrease; po0.05). We also ob-
served significant reductions in MPO activity levels with
RDP58 treatment in the ears of mice exposed to TPA
(po0.0001) (Fig 3B). The effectiveness of RDP58 was con-
centration dependent and comparable to betamethasone at
the 25 mg per mL concentration. A negative control peptide,
which lacks anti-inflammatory activity, had no protective
effect, ruling out generalized peptide-inhibiting conse-
quences.
Another important mechanism for cutaneous inflamma-
tion is the secretion of cytokines, such as IL-1 and IL-6, by
keratinocytes in response to injury (Kupper et al, 1989;
Kupper and Groves, 1995). A reduction in the secretion of
these two primary cytokines would be expected to result in
a decrease in cutaneous inflammation. As shown in Fig 4,
TPA treatment results in an increase in IL-1b and IL-6 pro-
tein levels in ear biopsy homogenates. Treatment with TPA
plus RDP58 reduced both IL-1b and IL-6 cytokine levels
significantly (50%–60% decrease; po0.001). The negative
control peptide was not effective in reducing the levels of
these cytokines. Thus, RDP58 may reduce the levels of ac-
tivated cellular infiltrates and local secretion of cytokines,
thereby reducing cutaneous inflammation.
Inhibition of pro-inﬂammatory mediators in keratin-
ocytes by RDP58 Since the topical application of RDP58
on the skin comes into contact mainly with the epidermis,
we also investigated the cytokine-inhibitory effect of the
drug specifically on keratinocytes. Primary normal human
epidermal keratinocytes (NHEK) were treated with one of
three different stimuli thought to mediate specific aspects of
cutaneous inflammation, including TNFa, IL-1b, or FBS, in
the presence or absence of RDP58 (50 mM). The production
of IL-1a and IL-6 in the supernatants was subsequently
evaluated by ELISA. The production of IL-1a by the NHEK
cells was elevated in all stimulation groups including the
unstimulated controls. This reflects the constitutive expres-
sion of the IL-1a isoform; however, RDP58 was able to
inhibit the production of IL-1a in these cells under all
conditions by approximately 80%–90% (Fig 5A). The pro-
duction of IL-6 by the NHEK cells was specifically increased
upon stimulation. RDP58 was able to inhibit the induced IL-
6 production mediated by each of the three different stimuli
in NHEK cells (Fig 5B). This confirms that RDP58 is capable
of mediating pro-inflammatory cytokine production stimu-
lated by different signals specifically in the keratinocyte.
Since mechanism of action studies for RDP58 demon-
strated an ability to reduce inflammation by targeting path-
ways that lead to the activation of the transcription factors
AP-1 and NF-kB (Lazarov et al, 2003), we decided to further
evaluate whether RDP58 treatment decreased the activity
of these transcription factors in keratinocytes. NHEK cells
were transiently transfected with luciferase-reporter con-
structs, stimulated with different inflammatory stimuli in the
presence or absence of RDP58, and then assayed for lucif-
erase activity, which served as an indicator of the direct
activation of the respective transcription factor. The tran-
scriptional activity of both NF-kB and AP-1 transcription
factors was moderately induced with FBS and IL-1b stim-
ulations (Fig 5C). The activation of the reporter constructs
was much more robust with the TNFa stimulation, indicating
a 3.1-fold induction of AP-1 activity and a 10.7-fold induc-
Figure3
Inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
myeloperoxidase (MPO) activity by rationally designed peptide 58
(RDP58). Neutrophil activation levels were determined by MPO activity
assay in dorsal skin (A) and ear (B) tissue homogenates of mice fol-
lowing TPA-induced contact dermatitis. Exposure to TPA resulted in a
marked increase in cutaneous MPO levels in the dorsal skin as com-
pared with acetone-vehicle alone (A). Treatment with 10 mg per mL
RDP58 30 min after TPA application significantly decreased cutaneous
MPO levels compared to vehicle treatment controls. Elevated levels of
MPO activity were also observed in the ears of TPA-induced mice (B).
RDP58 treatment reduced the level of MPO activity in a concentration-
dependent manner and was comparable to a positive control steroid,
0.05% betamethasone, at the highest concentration used. A negative
control peptide, which lacks anti-inflammatory activity, did not reduce
TPA-induced MPO activity. Data are presented as mean  SEM from at
least 3 experiments consisting of three to five animals per group in each
experiment. Values represent units of enzymatic activity in the dorsal
skin and as percent change in MPO activity relative to naı¨ve tissues for
the ear homogenates. Statistical significance was determined using
ANOVA with a post hoc Dunnett’s multiple comparison test; po0.05.
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tion of NF-kB activity. Remarkably, RDP58 was able to in-
hibit the transcriptional activity of both NF-kB and AP-1 in-
duced after all stimulation conditions to a level well below
the unstimulated background (Fig 5C). This is consistent
with the findings in other leukocyte and epithelial cell types
(Lazarov et al, 2003). The ability of RDP58 to inhibit the
activation of NF-kB and AP-1, which are critical for the
transcriptional regulation of a number of pro-inflammatory
cytokines, in keratinocytes suggests that it may effectively
modulate this important participant in cutaneous immune
responses.
RDP58 effectively suppresses prolonged inﬂammation
induced by repeated TPA application As a second in vivo
measure of the anti-inflammatory activity of RDP58, the
peptide was administered topically in three different dosing
schedules in a mouse model of chronic skin inflammation
induced by repeated exposure to phorbol ester. The skin
inflammation in this model is persistent and has been useful
in assessing whether topically applied compounds are able
to resolve an existing inflammatory lesion (Stanley et al,
1991). A 25 mg per mL solution of RDP58 markedly reduced
the edema, epidermal hyperplasia, and cell infiltration in this
model (Fig 6). Staining with the CD3 cell surface marker
revealed a major T cell component to the infiltrate popula-
tion, which was also reduced by RDP58 and betamethas-
one treatments. Consistent with the histopathology, RDP58
reduced the level of MPO activity in the inflamed skin with
reductions of 40%, 50%, and 70%, respectively, measured
in the one-, three-, or five-treatment dosing schedules (Fig
7). These findings support the ability of RDP58 to resolve an
existing, persistent inflammatory lesion with a single appli-
cation and even more effectively with multiple topical appli-
cations to a level comparable with corticosteroid treatment.
Discussion
This study provides evidence that RDP58, when applied
topically, has anti-inflammatory activity in the skin. In animal
models of both acute and chronic irritant contact dermatitis,
we showed that topical treatment with RDP58 markedly
reduces cutaneous inflammation. This was supported by
observed reductions in skin thickness and weight, amelio-
ration of several histopathological indicators, and direct
measurement of decreased pro-inflammatory cytokines and
neutrophil activation. We also were able to demonstrate the
ability of RDP58 to specifically act on keratinocytes, with
reductions in cytokine expression and transcription factor
activation, which supports the previously described mech-
anism of action.
By the nature of its mechanism of action, RDP58 has
broad immunomodulatory activity and may prove beneficial
for several different inflammatory disorders. The limited
bioavailability of RDP58, however, makes it best suited for
clinical indications that can be treated with topical thera-
peutics. Although the skin is an easily accessible tissue for
topical administration, its barrier functions pose enormous
challenges for most therapeutics. The biophysical proper-
ties relating to size and charge of the RDP58 peptide are not
optimal for skin penetration. In this proof of concept study,
we do not use formulations to facilitate delivery; however,
the mouse skin barrier is relatively easy to penetrate and we
may also be taking advantage of a disrupted lipid barrier
caused by the acetone in the TPA applied prior to treatment.
We are currently testing formulations with skin penetration-
enhancing properties to optimize the stability and delivery of
the RDP58 peptide.
It is widely recognized that the secretions of cytokines by
keratinocytes in response to injury are key mediators of the
cutaneous inflammatory response (Piguet, 1993; Murphy
et al, 2000). In this study, we demonstrated that topical
treatment with RDP58 inhibits the secretion of IL-1 and IL-6
Figure 4
Inhibition of intrerleukin (IL)-1 and IL-6 production by rationally
designed peptide 58 (RDP58) in 12-O-tetradecanoylphorbol-13-ac-
etate (TPA)-induced irritant dermatitis. Ear punch biopsies were
taken 18 h following the induction of TPA-induced contact dermatitis,
and tissue homogenates were examined for cytokine production using
ELISA. Cytokine levels were calculated as pg per mg total protein and
then expressed as percent change relative to naı¨ve ear homogenates.
Exposure to TPA resulted in a marked increase in cutaneous levels of
both IL-1 (A) and IL-6 (B). Treatment with 10 mg per mL RDP58 30 min
after TPA application significantly decreased the production of these
cytokines. The positive control steroid, 0.05% betamethasone, effec-
tively reduced both IL-1 and IL6 to near-background levels and below
that achieved for RDP58 at the 10 mg per mL concentration. A negative
control peptide, which lacks anti-inflammatory activity, did not signif-
icantly reduce TPA-induced production of IL-1 and IL-6. Data are pre-
sented as mean  SEM from to to three experiments consisting of
three to five animals per group in each experiment. Statistical signif-
icance was determined using ANOVA with a post hoc Dunnett’s mul-
tiple comparison test; po0.05.
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in the acute irritant contact dermatitis model of inflamma-
tion. It is likely that this inhibition of cytokine secretion
at least partially accounts the reduction in inflammation
observed in these studies. RDP58 was also shown to reduce
these cytokines in cultured keratinocytes. The transcription
of cytokines, such as IL-1, IL-6, and TNFa, and many of the
effectors of cytokine action, such as vascular cell adhesion
molecule-1, and cyclo-oxygenase-2, are regulated by NF-
kB (Baeuerle and Baltimore, 1996; Ghosh et al, 1998).
RDP58 is known to interfere with NF-kB activation by dis-
rupting upstream signaling events and demonstrated as
much in this study with keratinocytes. In addition, other
mechanisms could contribute to the anti-inflammatory
properties of RDP58. Specifically, RDP58 negatively
interferes with AP-1 transcription pathways and this tran-
scription factor is known to have important roles in the in-
flammatory process (Karin et al, 1993). Furthermore, RDP58
induces heme oxygenase-1, which would reduce oxidative
stress that would also be anti-inflammatory (Fuchs et al,
2001). Thus, there are a number of different mechanisms
that could contribute to the anti-inflammatory response of
RDP58 treatment.
The magnitude of the inhibition of cutaneous inflamma-
tion induced by treatment with RDP58 was similar to that
observed after topical treatment with a potent corticoster-
oid, betamethasone. It is well recognized that, whereas
steroids have potent anti-inflammatory effects, they can al-
so induce systemic side-effects, including immune sup-
pression that may limit their clinical usefulness (Ashwell et al,
2000). Due to the limited bioavailability of RDP58, it is likely
that the anti-inflammatory effects will be more localized and
less global than the effects of steroids, which could be
beneficial in the long-term treatment of inflammatory con-
ditions localized to the skin. Several specific cytokine and
chemokine inhibitors are also currently in development as
therapeutics for a number of inflammatory and autoimmune
diseases. These therapies, however, focus mainly on the
inhibition of one specific cytokine or chemokine. Conversely,
Figure 5
Inhibition of pro-inflammatory mediators in primary keratinocytes by rationally designed peptide 58 (RDP58). Primary normal human
epidermal kerationocytes (NHEK) cells were stimulated with either fetal bovine serum, interleukin (IL)-1b, or tumor necrosis factor alpha in the
presence or absence of 50 mM RDP58. The production of IL-1a (A) and IL-6 (B) in the supernatant was then evaluated by ELISA. IL-1a levels were
markedly elevated under all stimulation conditions. The background concentration observed in unstimulated cells suggests a high constitutive
expression level in the keratinocyte. RDP58 treatment substantially reduced levels of IL-1a produced in all stimulation groups (A). IL-6 was
specifically induced by each stimulus, but in all cases, treatment with RDP58 reduced cytokine production (B). The effect of RDP58 on the
transcriptional activity of nuclear factor-kB (NF-kB) (C) and AP-1 (D) was evaluated by transiently transfecting NHEK cells with luciferase-reporter
constructs. The cells were then stimulated in the presence or absence of RDP58 and the luciferase activity was calculated as the fold activation
relative to unstimulated and untreated cells. Although activation levels varied between stimuli, in all cases, RDP58 treatment was able to sub-
stantially reduce both NF-kB and AP-1 activation to levels below background.
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Figure 6
Rationally designed peptide 58 (RDP58) ameliorates the compounding inflammatory damage brought on by chronic 12-O-tetra-
decanoylphorbol-13-acetate (TPA) exposure. Female CD-1 mice were treated with 0.01% TPA in acetone applied to the inner and outer surfaces
of the ear every other day for 5 d. RDP58 (25 mg per mL) or betamethasone (0.05%) was applied topically to the right ear after 30 min following each
TPA application. Skin punch biopsies from control and treated ears of each mouse were harvested for histological analysis 18–20 h following the
final TPA treatment. Hematoxylin- and eosin-stained sections of chronic TPA-induced contact dermatitis reveal marked increases in ear thickness
accompanied by severe edema, epidermal hyperplasia, and inflammatory cell infiltration (A). RDP58 treatment (C) reduces ear thickness and the
associated pathological indicators to an extent comparable with betamethasone (B). Immunohistochemical staining with the CD3 cell-surface
marker indicated a substantial infiltration of T-cells after the 5 d of TPA application (D). With betamethasone (E) and RDP58 (F) treatment CD3
staining is reduced. Sections shown are representative of observations from four animals in each group.
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since so many cytokines are involved in these inflammatory
and autoimmune diseases, drugs such as RDP58 that inhibit
multiple cytokines pathways may prove to be more useful.
In summary, this study demonstrates that topical appli-
cation of RDP58 has an anti-inflammatory action in both
chronic and acute irritant contact dermatitis. Coupled with
the previously described effects of RDP58 in the UVB-in-
duced skin inflammation model makes it likely that this
platform therapeutic will be useful in the treatment of a va-
riety of cutaneous disorders.
Materials and Methods
Experimental animals and reagents Six-to 8-wk-old female FVB/
N mice (Harlan, Hollister, California) and CD-1 mice (Charles Rivers,
Wilmington, Massachusetts) were maintained in the animal facility
at Sangstat Medical Corporation. Animals were housed under
conventional conditions with laboratory chow and water accessible
ad libitum, and maintained for at least 1 wk prior to inclusion in
experiments. All animal procedures were conducted in compliance
with the NIH Guide for the Care and Use of Laboratory Animals and
approved by the Sangstat Medical Corporation IACUC. All chem-
icals were purchased from Sigma (St Louis, Missouri) unless oth-
erwise noted. Peptides (RDP58: NH2-r-nle-nle-nle-r-nle-nle-nle-g-
y-CONH2, negative control peptide: NH2–nle–nle–nle–r–r–nle–nle–
r–g–r–CONH2) were synthesized using a solution-phase process,
purified by HPLC and shown to be of equal or greater than X98%
purity by analytical HPLC (UCB Bioproducts, Brussels, Belgium).
Betamethasone dipropriate cream (USP, 0.05%, Fougera Melville,
New York), a synthetic adrenocorticosteroid, was used as a pos-
itive treatment control.
Treatments and tissue preparation Acute irritant contact der-
matitis was induced in groups of five female FVB/N mice by a
single topical application of 10 mL of 0.03% (wt/vol in acetone) TPA
on the inner and outer surfaces of both ears (Sheu et al, 2002).
RDP58, dissolved in water at concentrations ranging from 2 to 25
mg per mL, was applied to the right ear at 30 min following in-
flammatory insult with TPA in one group of animals. In a separate
set of animals, acetone alone was applied to both ears as a vehicle
control. A total of 20 mL of test compound or vehicle was applied to
each surface of the right and left ears, respectively. As additional
controls, 0.05% betamethasone was used as a positive control
and a similar peptide lacking anti-inflammatory activity was used
as a negative control. At 18 h, when TPA-induced inflammation is
maximal, animals were euthanized by CO2 asphyxiation and ear
thickness was measured with a digital caliper (VWR, West Chester,
Pennsylvania). The difference in thickness between treated right
ear and control TPA left ear of each mouse was calculated as a
percent decrease, and then normalized to the difference relative to
naı¨ve ear thickness. This was immediately followed by 5 mm ear
punch biopsies being taken for weight determinations, biochemical
analysis, and histology. Alternatively, TPA treatment was conduct-
ed by painting 5 mg of TPA in 200 mL acetone on the dorsal skin of
mice. Briefly, the back of each mouse was shaved 2 d before each
experiment, and RDP58 was applied topically to the shaved area of
the dorsal skin 30 min after application of the TPA/acetone solu-
tion. Skin thickness was measured before TPA application and 18 h
after using digital calipers on a fold of skin in the center of the
shaved area. The change in dorsal skin thickness was calculated
from the difference between these timepoints. A total of six 5mm
biopsy punches were taken from an approximately 2 cm  2 cm
shaved treatment area for biochemical analyses and histology. The
tissue weight was calculated from the sum of four of these biopsy
punches prior to freezing.
A chronic persistent skin inflammation was induced in the ears
of CD-1 mice (five per group) by the repeated treatment of phorbol
ester using the procedure of Stanley et al (1991). TPA (10 mL,
0.01% in acetone) was applied to ears on days 0, 2, 4, 6, and 8.
RDP58 in water was applied 30 min after TPA according to one of
the following treatment schedules: (1) a single treatment following
the fifth and final TPA application, (2) three treatments beginning
with the third TPA application, or (3) following each of the five TPA
applications. 18 h after the last application, ear punch biopsies
were removed and either snap-frozen for later analysis of my-
eloperoxidase content or fixed in 10% buffered formalin (Fisher
Scientific, Hampton, New Hampshire) for histological evaluation.
Histology For histological assessment of cutaneous inflammation,
biopsies from control and treated ears of mice in each treatment
group were collected and fixed in 10% neutral-buffered formalin
(Fisher Scientific). The preparation of tissues by embedding in par-
affin, sectioning, and staining was carried out by QualTek Molec-
ular Laboratories (Santa Barbara, California). A series of ear cross
sections were prepared for the evaluation of general cutaneous
inflammation parameters using H&E stain. The identification of T
cell-specific infiltration in the chronic inflammation studies utilized
immunohistochemistry with the CD3 cell-surface marker. Subse-
quent analysis of stained tissue sections was carried out in a
blinded fashion by trained investigators. All sections were exam-
ined using standard bright-field optics (Zeiss, Axioskop 40 Zeiss,
Thornwood, New York).
MPO activity assay MPO activity can be used as a quantitative
measure of the extent of infiltration of polymorphonuclear ne-
utrophils into the inflamed tissue (Bradley et al, 1982). Following
treatment, as described above, 5 mm skin punches collected from
either the dorsal skin or ear of each mouse were homogenized in
1 mL of T-PER protein extraction reagent (Pierce, Rockford, Illinois)
Figure 7
Rationally designed peptide 58 (RDP58) reduces myeloperoxidase
(MPO) levels induced by chronic 12-O-tetradecanoylphorbol-13-
acetate (TPA) exposure. Neutrophil activation levels were determined
by MPO activity assay in ear tissue homogenates from mice following
chronic TPA-induced contact dermatitis. Chronic exposure to TPA,
every other day for 5 d, resulted in a marked increase in cutaneous
MPO levels in the ear. The value for this group was set as a 100%
change in MPO activity relative to naı¨ve ear tissue. Treatment with
RDP58 (25 mg per mL in water) or betamethasone (0.05%) was carried
out according to one of the following schedules: (1) a single treatment
following the fifth and final TPA application (1  ); (2) three treatments
beginning with the third TPA application (3  ); or (3) following each of
the five TPA applications (5  ). All three treatment courses with RDP58
reduced cutaneous MPO levels induced by the chronic TPA exposure
to an extent comparable to the positive control steroid, betamethas-
one. Data are presented as mean  SEM from two experiments with
three to five animals per group in each experiment. Values represented
as percent change in MPO activity relative to naı¨ve ear tissue. Statis-
tical significance was determined using ANOVA with a post hoc Dun-
nett’s multiple comparison test; po0.05.
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containing a protease inhibitor cocktail (Sigma) using the FastPrep
System (Qbiogene, Carlsbad, California). Homogenates were then
centrifuged at 16,000  g for 30 min, and MPO activity was meas-
ured by adding 100 mL of supernatant to 200 mL of an assay re-
action mixture containing 0.5% hexadecyltrimethylammonium
bromide (in 50 mM potassium phosphate, pH 6.4), 0.165 mg per
mL o-dianisidine dihydrochloride, and 0.0015 % H2O2. After a 30-
min incubation period at room temperature, absorbance at 450 nm
was measured. Absolute MPO activity was determined based on
the generation of a standard curve.
Cytokine expression analysis Cytokine protein levels for IL-1b
and IL-6 were determined in the ear biopsy homogenates, pre-
pared as described above for the MPO assay, using ELISA kits
following the manufacturer’s instructions (BioSource, Camarillo,
California). Absorbances were measured at 450 nm with a Micro-
plate Reader (Molecular Devices, Sunnyvale, California). Total pro-
tein was determined using the BCA assay (Pierce). Cytokine
content was calculated as pg per mg total protein, and then ex-
pressed as percent change relative to naı¨ve tissue.
Keratinocytes Primary NHEK (Clonetics, San Diego, California)
were cultured in keratinocyte cell medium (Clonetics) supplement-
ed with KGM2 Bullet Kit (Clonetics). Cell density was not allowed to
exceed 70%. RDP58 was dissolved to make a 1 mg per mL stock
solution in double-processed tissue culture grade water (Sigma).
The RDP58 stock solution was stored at 201C until use. The pri-
mary NHEK cells were plated at 60% confluency and treated with
the following stimuli: 50 ng per mL TNFa (Peprotech, Rocky Hill,
New Jersey), 50 ng per mL IL-1b (Peprotech), or 5% FBS (ATCC,
Manassas, Virginia), in the presence or absence of RDP58 (50 mM).
Cell culture supernatants were assayed by ELISA for human IL-
1a and IL-6 using the corresponding DuoSet kits (R&D Systems,
Minneapolis, Minnesota) according to the manufacturer’s instruc-
tions. The absorbance was measure at 450nm with a Microplate
Reader (Molecular Devices). For transient transfection assays using
luciferase reporter constructs, NHEK cells were transfected in six-
well plates at 50% confluency with a total of 4 mg DNA per well
using Fugene6 (Roche, Indianapolis, Indiana) according to the
manufacturer’s instructions. The luciferase reporter plasmids pNF-
kB-Luc and pAP1-Luc were obtained from Stratagene (La Jolla,
California). 20–24 h after transfection, cells were subcultured and
stimulated in black 96-well plates (ViewPlate, Perkin-Elmer, Boston,
Massachusetts). Cell culture supernatants were harvested 20–24 h
after stimulation, and the luciferase activity in the cell lysates was
measured using Steady-Glo Luciferase Assay (Promega, Madison,
Wisconsin) according to the manufacturer’s instructions. Lumines-
cence was read on a Victor2 Wallac luminometer (Perkin-Elmer).
Statistical analysis Data are presented as mean values  SEM.
When comparisons were made between two groups statistical
significances were determined using Student’s unpaired t test.
When comparisons were made between multiple groups, statisti-
cal significances were determined using ANOVA, with post hoc
comparisons by Dunnett’s Multiple Comparison Test. A p value
less than 0.05 was considered significant. All statistical analyses
were performed using GraphPad Prism version 3.03 for Windows
(GraphPad Software, San Diego, California).
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